Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tislelizumab + anlotinib + platinum-based chemotherapy
- Development stage
- Unknown
- Lead developer
- BeiGene
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
tislelizumab + anlotinib + platinum-based chemotherapy is a combination regimen being evaluated for the perioperative treatment of resectable non-small cell lung cancer (NSCLC). The regimen consists of tislelizumab, a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor to enhance T-cell mediated anti-tumor immunity; anlotinib, a multi-targeted tyrosine kinase inhibitor that provides antiangiogenic effects by inhibiting VEGFR, FGFR, PDGFR, and c-Kit; and a platinum-doublet chemotherapy backbone (such as cisplatin or carboplatin combined with pemetrexed or paclitaxel). This therapeutic approach, investigated by Tangdu Hospital, aims to improve pathological complete response (pCR) rates by combining immune checkpoint inhibition, antiangiogenesis, and cytotoxic chemotherapy in the neoadjuvant setting, followed by adjuvant immunotherapy.
- Brand names
- TevimbraFukanghua
- Other names
- Tislelizumab + Anlotinib + ChemotherapyImmunochemotherapy combined with antiangiogenic (Tang-Du Hospital)immunochemotherapy + antiangiogenic-Tang-Du Hospital-non-small cell lung cancer
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)FGFR1 (Fibroblast growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR3 (Fibroblast growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)DNAVEGFR3 (Vascular endothelial growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)
Beyond the preview
Go deeper on tislelizumab + anlotinib + platinum-based chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tislelizumab + anlotinib + platinum-based chemotherapy.